FDA approves Stiefel Fabior (0.1%)
-
Last Update: 2012-05-14
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: Stiefel, a subsidiary of China pharmaceutical promotion association 2012-05-14 GlaxoSmithKline Co, said on Friday that the US Food and Drug Administration had approved Fabior (0.1%) new drug application Fabior is the only topical foamed prescription of retinoic acid for acne vulgaris aged 12 and over Stiefel is committed to meeting the needs of patients and Department of dermatology experts We believe that Fabior foam will be an important treatment option for patients with moderate to severe acne "Said Jean Christophe may, vice president, dermatology, stiefel North America The approval of the bubble was based on two multicenter, randomized, double-blind, and solvent controlled phase III trials in the United States and Canada Original link: http://
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
